NCT01128634已完成1 期
A Single-Centre, Randomised, Open-label Study to Evaluate the Effects of Steady-State Verapamil, a Moderate P-Glycoprotein and CYP3A4 Inhibitor, on the Pharmacokinetics of GSK573719 and GSK573719 in Combination With GW642444
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Pharmacokinetic parameters of plasma and urine
研究概览
简要总结
The purpose of this study is to see if the Pharmacokinetics and the Safety Profile of GSK573719 and GSK573719/GW642444 are effected by concurrent dosing with the PGP inhibitor verapamil.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •AST, ALT, alkaline phosphatase and bilirubin < 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
- •Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- •A female subject is eligible to participate if she is of: non childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy, double oophorectomy or bilateral salpingectomy., or postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL and estradiol < 40 pg/ml (<140 pmol/L) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •Male subjects must agree to use one of the contraception methods listed in Section 8.
- •This criterion must be followed from the time of the first dose of study medication until completion of the follow up visit.
- •Body weight > 45 kg and BMI within the range 18 - 28 kg/m2 (inclusive).
- •Capable of giving written informed consent and a signed and dated written informed consent is obtained, which includes compliance with the requirements and restrictions listed in the consent form.
- •Normal spirometry (FEV1 ≥ 80% of predicted, FEV1/FVC ≥ 70%).
- •Non-smokers (never smoked or not smoking for >6 months with <10 pack years history (Pack years = (cigarettes per day smoked/20) x number of years smoked))
- •Available to complete the study
排除标准
- •Any clinically important abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, ECG (12-lead) or from 24hr Holter monitoring. If the Investigator and the GSK Medical Monitor agree that a finding is unlikely to introduce additional risk factors and will not interfere with the study procedures a subject can be included.
- •A mean QTc(B) value at screening >450msec, or an ECG that is not suitable for QT measurements (e.g. LBBB or poorly defined termination of the T wave).
- •A history of elevated resting blood pressure or a mean blood pressure higher than 140/90 mmHg at screening.
- •A mean heart rate outside the range 40-90 bpm at screening.
- •The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates and benzodiazepines. The detection of drugs with a legitimate medical use would not necessarily be an exclusion to study participation. The detection of alcohol would not be an exclusion at screening but would need to be negative pre-dose and during the study.
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome).
- •A positive test for HIV antibody (if testing required by local SOP's).
- •History of regular alcohol consumption within 3months of the study defined as:
- •an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males), or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint (220mL) of beer or 1 (25ml) measure of spirits or 1 glass (125ml) of wine.
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- •History of sensitivity to any of the study medications, verapamil or components thereof, known allergy or hypersensitivity to milk protein or the excipients lactose monohydrate and MgSt, or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •The subject is unable to use the novel dry powder inhaler correctly.
- •The subject has a known allergy or hypersensitivity to ipratropium bromide, tiotropium, atropine and any of its derivatives.
- •Any adverse reaction including immediate or delayed hypersensitivity to any β2 agonist or sympathomimetic drug,.
- •Subject is kept under regulatory of judicial order in an institution.
- •Subject is mentally or legally incapacitated.
研究组 & 干预措施
GSK573719
Other
GSK573719
干预措施: GSK573719 (Drug)
GSK573719/GW642444
Other
GSK573719/GW642444
干预措施: GW573719/GW573719 (Drug)
结局指标
主要结局
Pharmacokinetic parameters of plasma and urine
时间窗: 15 days
次要结局
- General safety and tolerability endpoints: adverse events, heart rate, systolic and diastolic blood pressure, 12- lead ECG (QTc(B), QTc(F)) and clinical laboratory safety tests. 24hr Holter monitoring(From first dose on day 1 through to Follow Up visit)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveNCT00950807GlaxoSmithKline176
已完成
2 期
Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With AsthmaAsthmaNCT01573624GlaxoSmithKline421
已完成
1 期
A Healthy Volunteer Study With Inhaled GSK573719 and PlaceboPulmonary Disease, Chronic ObstructiveNCT00803673GlaxoSmithKline36
已完成
1 期
GSK1349572 First Time in Human StudyHealthy SubjectsNCT00555035GlaxoSmithKline20
已完成
2 期
28-day Repeat Dose Study of GSK573719Pulmonary Disease, Chronic ObstructiveNCT01030965GlaxoSmithKline285